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Abstract
Purpose of Review Episodic hypoglycemia is an almost inev-
itable consequence of exogenous insulin treatment of type 1
diabetes, and in up to 30% of patients, this can lead to im-
paired awareness of hypoglycemia. This predisposes to recur-
rent severe hypoglycemia and has a huge impact on quality of
life. Although many patients can get resolution of severe hy-
poglycemia through novel education and technology, some
patients continue to have ongoing life-threatening hypoglyce-
mia. Islet transplantation offers an alternative therapeutic op-
tion for these patients, in whom these conventional ap-
proaches have been unsuccessful. This review discusses the
selection process of identifying suitable candidates based on
recent clinical data.
Recent Findings Results from studies of islet transplantation
suggest the optimal recipient characteristics for successful is-
let transplantation include age >35 years, insulin requirements
<1.0/kg, and weight >85 kg.
Summary Islet transplantation can completely resolve hypo-
glycemia and near-normalize glucose levels, achieving insulin
independence for a limited period of time in up to 40% of
patients. The selection of appropriate candidates, optimizing
donor selection, the use of an optimized protocol for islet cell
extraction, and immunosuppression therapy have been proved
to be the key criteria for a favorable outcome in islet
transplantation.
Keywords Type 1 diabetes . Islet cell transplantation .
Hypoglycemia . Impairedawarenessofhypoglycemia .Severe
hypoglycemia . Transplantation
Introduction
Type 1 diabetes mellitus (T1DM), caused by autoimmune de-
struction of insulin-producing beta cells, is treated with exoge-
nous insulin therapy. In health, the production of insulin is very
controlled, allowing stable glucose values despite food, exer-
cise, or illness. Pharmacological replacement using current
tools is very blunt, even in patients using modern technology
such as insulin pumps and, certainly, for the majority of patients
who use multiple daily injections to try and mimic physiolog-
ical requirements [1]. They are limited by slow onset and
prolonged duration of action of even the most rapid acting
insulin analogs used to cover meal time requirements, and
peaks and variability in the pharmacokinetics of currently avail-
able long-acting insulin analogs required to cover basal require-
ments. Ongoing management and attainment of glucose levels
that reduce the risk of micro- andmacro-vascular complications
requires frequent glucose monitoring, and multiple decisions
every day around food, insulin and activity. This places signif-
icant burden on the person with diabetes, often termed diabetes
distress and leading to increased rates of depression [2]. It is not
surprising that many if not most people with T1DM are unable
to achieve optimal glucose control [3]. Given the pharmacolog-
ical barriers, the risk of striving to minimize high glucose levels
is excessive exposure to hypoglycemia. This comes with its
own risks including confusion, injury, unconsciousness and
even in rare cases death [4]. Repeated exposure to glucose
levels below 3 mmol/l can blunt physiological warning signs
leading to impaired awareness of hypoglycemia [IAH] that in-
creases the risk of severe hypoglycemia 3–6 fold [5].
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In this setting, cellular therapy providing biological insulin
replacement therapy for patients with T1DM has been an at-
tractive option for decades. The first reported cases of pancre-
atic tissue transplants for this purpose where performed by Dr.
Frederick Pybus and date back to 1916 [6]. However, it wasn’t
until years later, in 1990, when Tzakis et al.[7] reported the
first successful islet cell transplantation (ICT) whereby they
used an islet isolation method that was first developed by Dr.
Paul Lacy [8] and later modified by Dr. Camillo Ricordi [9].
The landmark report of seven consecutive patients achieving
insulin independence by Shapiro et al. in 2000 [10], signaled a
surge in interest and a number of centers worldwide started
offering ICT based on the Edmonton protocol, which included
a steroid-free immunosuppression regimen and multiple do-
nor islets. This protocol still forms the basis of ICT protocols
used worldwide in islet transplant centers.
Recent data published by the Collaborative Islet Transplant
Registry (CITR) showed that the efficacy and safety of this
treatment has significantly improved over the last 15 years.
While insulin independence is considered to be the primary
end-point in most clinical trials of ICTs, it is certainly not the
only benefit it offers. The CITR [11••] report indicated that in
the presence of even moderate amounts of endogenous C-
peptide, there was significant improvement in glycated hemo-
globin (HbA1c), which is the crucial factor in reducing the
risk of developing chronic complications of diabetes such as
those affecting the vasculature and peripheral nerves. More
importantly, there was a reduction and in most cases complete
abolition of severe hypoglycemic episodes, with resolution of
IAH in these patients. Therefore, ICT can offer an alternative
form of treatment for patients with T1DMwho cannot achieve
adequate glycemic control using intensive exogenous insulin
treatment and suffer from debilitating recurrent hypoglycemic
episodes.
In this review, we will discuss the selection process in iden-
tifying suitable ICT recipients based on the current clinical data.
Current Clinical Data on Islet Cell Transplantation
A key change in emphasis for the outcomes of ICT was trig-
gered by the selection of patients with recurrent severe hypo-
glycemia in the landmark trial by Shapiro et al.[10]. Other
important elements were steroid-free immunosuppression
with dacluzimab induction and low-dose tacrolimus and
daclizumab for maintenance. In 2006, the Immune Tolerance
Network study presented the results of this multicenter phase
1–2 trial, with participants from nine international centers: six
in North America and three in Europe, where they investigat-
ed the feasibility and reproducibility of the Edmonton protocol
across the different centers [12]. Similarly to the aforemen-
tioned trial, the eligibility criteria included undetectable C-
peptide levels, T1DM for >5 years with recurrent
neuroglycopaenia, IAH, and severe glycemic lability and ages
between 18 and 65 years old. The islet infusion requirements
included the ABO blood group compatibility and an islet mass
of ≥5000 IEQs/kg of recipient’s body weight for the initial
infusion, with a cumulative mass of over 10,000 IEQ’s deliv-
ered with at least two infusions, unless insulin independence
was achieved with a single infusion. At 12 months, post final
transplantation, 16 of 36 participants (44%) had reached the
primary end point, i.e., were insulin independent, 10 partici-
pants (28%) had partial graft function, and 10 participants
(28%) had complete graft loss.
In 2005, Hering et al. [13] reported the results of a prospec-
tive, single-center, 1-year follow-up pilot trial where the primary
outcomewas insulin independence in the first year after a single-
donor islet transplant. Again, this study targeted adult patients
with labile glucose levels and IAH. Immunosuppression was
more aggressive, with induction using rabbit antithymocyte
globulin (rATG), methylprednisolone, daclizumab, and
etanercept. Maintenance immunosuppression was initiated with
sirolimus and reduced-dose tacrolimus, which was gradually
replaced with mycophenolate mofetil one month post-transplan-
tation. All eight recipients became insulin independent and did
not experience further hypoglycemic episodes. Of the eight re-
cipients, five remained insulin independent for longer than one
year and the rest were insulin-independent for 121, 76, and
7 days. They concluded that contributing factors to their high
success rate were excluding pancreata from donors older than
50 years, limiting cold storage to less than 8 h and using the two-
layer preservation method, avoiding use of Ficoll during islet
purification, and culturing islets pre-transplantation. With regard
to immunosuppression, it is possible that etanercept could also
contribute to the high success rate, as it was the new addition to
this trial compared to the group’s previous trial [14]. In addition,
replacing or minimizing tacrolimus at 1 month post-
transplantation may have enhanced the function of engrafted
islets.
The latest data on ICT are from the Clinical Islet
Transplantation (CIT) Consortium study, a phase 3 registra-
tion trial, designed to enable licensure of the islet product
[15•]. In this study, the participants enrolled were 26.2–
65.5 years old, duration of diabetes was 11–57 years, median
HbA1c was 7.2% (range, 5.7–9.2) or 55 mmol/mol (range,
39–77), with absent stimulated C-peptide levels, and docu-
mented IAH. The exclusion criteria for the study were BMI
>30 kg/m2, weight ≤50 kg, insulin requirements >1.0 units/kg/
day or <15 units/day, HbA1c level >10% (86 mmol/mol),
measured GFR <80 mL/min/1.73m2, history of panel reactive
anti-HLA antibodies by flow cytometry, and significant co-
morbidities. Forty-eight subjects were recruited of which 22
subjects received one infusion, 25 received two infusions, and
one subject received three infusions. The subjects were given
immunosuppression including rATG and etanercept for the
first transplant and etanercept with basiliximab at subsequent
transplants. Sirolimus and tacrolimus were used for
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maintenance. The purified human pancreatic islets were
manufactured using a standardized method [16]. The primary
end point was defined as an HbA1c level of <7.0% (53 mmol/
mol) at day 365 with no severe hypoglycemic episodes from
day 28 to day 365 after the first islet transplant and was
achieved by 42 of the 48 subjects (87.5%). Additionally, 11
subjects achieved insulin independence at day 75, 25, at day
365 and 20 remained insulin independent at day 730. In terms
of safety, the authors reported that serious adverse events at-
tributed to the treatment included transplant procedure-related
bleeding in 5 of 56 percutaneous cannulations of a portal vein,
two infections as a consequence to immunosuppression, and
decrease in median GFR. It decreased from 102 ml/min/
1.73 m2 (range, 80–130) at baseline to 90 ml/min/1.73 m2 at
day 365 (P= 0.0008 vs. baseline, range, 59–129 ml/min/
1.73 m2).
The CITR collects and publishes data of the islet cell trans-
plant units in North America, Europe, and Australia where the
patients have given written informed consent. It is worth not-
ing that in the USA, ICT is experimental but at the Canadian,
European, and Australian sites, the treatment is available both
as part of a trial or standard of care. In 2013, they published
the most recent report which analyzed the data from the pa-
tients who received ICT from 1999 to 2012 [11••]. A total of
864 patients received an allogeneic islet transplant of which,
686 were islet transplant alone and 178 following or with a
simultaneous kidney transplant, and received a total 1679 in-
fusions from 2146 donors. The recipients were 7–72 years old
(mean 45±10SD), had T1DM for 2–61 years (29±11), and
had poor glycemic control. Poor glycemic control was defined
as frequent episodes of hypoglycemia, severe hypoglycemic
episodes, blood glucose lability, and HbA1c >8% [11••]. Over
the years, recipient characteristics have been changes in both
donor and recipient characteristics. Donors have been getting
older with higher BMI, and recipients have also been getting
older with higher HbA1c and increased use of continuous
subcutaneous insulin infusion (CSII) prior to transplantation.
There has also been a change in outcomes that has been
attributed to some extent to change in immunosuppression,
with more routine use of T cell depletion with or without
TNF antagonists. This has been associated with an increase
in 5-year graft survival [11••]. The latest CITR data suggest up
to 50% of patient can achieve insulin independence, with over
70% maintaining protection from severe hypoglycemia over
5 years.
Stepwise Approach to Recurrent Severe Hypoglycemia
The data presented show that while ICT can achieve insulin
independence for a proportion of recipients, it is most effective
at resolving problematic hypoglycemia. In particular, it is the
ability to do this while achieving optimal glucose control. For
this reason, in most countries where ICT is available, the main
indication is persistent problematic and recurrent episodes of
severe hypoglycemia despite optimal medical therapy. Severe
hypoglycemia, defined as “an event requiring assistance of
another person to actively administer carbohydrates, gluca-
gon, or take other corrective actions,” occurs in around 25%
[17] of patients with T1DM and contributes to substantial
morbidity [18].
The first step is identifying patients at high risk of severe
hypoglycemic episodes (SHE) (Fig. 1), and the main predic-
tors are duration of diabetes, age, IAH, and previous episode
of SHE. For this reason, we advocate routine screening for
IAH, just as we would do for microalbuminuria using validat-
ed assessment tools that have been shown to predict further
episodes of SHE. The most common are the Gold score [19],
the Clarke score [20], and the Pedersen-Bjergaard score [21].
Meticulous avoidance of mild hypoglycemia has been shown
to restore awareness in experimental settings [22]. In those with
IAH, at increased risk of SHE, structured education programs
have been shown to reduce severe hypoglycemia incidence and
restore awareness in about 50% of patients [17]. A recent sys-
tematic review of interventions to restore awareness showed that
these programs, characterized by 25–30 h of curriculum-based
education delivered in groups over 1–5 weeks, demonstrated a
halving of severe hypoglycemia rates [23]. These relatively
cheap interventions have lasting effects and are cost effective
[24]. For those who continue to have problematic hypoglycemia
despite structured education, there are observational data demon-
strating significant reductions in mild and severe hypoglycemia
with CSII via insulin pump therapy [25, 26], borne out by meta-
analysis showing a fourfold reduction in rates of severe hypogly-
cemia, with greatest reductions in those with highest baseline
rates of hypoglycemia [27].
The advent of continuous glucose monitoring (CGM) that
can alert and warn patients of impending hypoglycemia and,
in particular, systems that integrate CGM data CSII systems
capable of suspending insulin delivery in the presence of
sensor-detected hypoglycemia have made a huge difference.
In initial studies, those with high risk of severe hypoglycemia
and IAH were excluded, which is why some of the earlier
studies with CGM failed to show any reduction in hypogly-
cemia [28]. However, studies targeting those with IAH and
using automated threshold suspend systems have shown sig-
nificant reductions in severe hypoglycemia rates [29, 30]. The
latest generation of CSII, the Medtronic 640G, can stop insu-
lin delivery when it predicts hypoglycemia and has shown a
reduction in hypoglycemia events [31]. Closed loop systems,
that deliver insulin based on sensor glucose values, have been
tested in short duration clinical trials for up to 3 months [32].
Some systems use insulin alone, but there are other systems in
development that see both insulin and glucagon, more akin to
a human pancreas, and theoretically better equipped to deal
with problematic hypoglycemia. However, these “dual hor-
mone” systems come with increased complexity, and
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currently available glucagon is not stable in solution for these
to be commercially viable as yet. Most importantly, although
both single and dual hormone systems improve glucose con-
trol and reduce hypoglycemia, these systems have not yet
been tested in the high-risk IAH population.
The HypoCOMPASS trial randomized participants with
IAH in a 2×2 algorithm to CSII or multi-dose insulin and
CGM or self-monitoring of blood glucose. All patients were
seen frequently over 6 months, and there was similar reduc-
tion in SHE from 8.9 to 0.8 events/year, with no difference
between groups [33]. This study really highlights the impor-
tance of frequent contact and support to these patients. This
evidence base for the approach to patients with problematic
hypoglycemia was assimilated in a recent publication [34]. A
recent publication demonstrated that following this algorithm,
up to two thirds of patients with recurrent severe hypoglyce-
mia can be managed conservatively, with resolution of severe
hypoglycemia. However, islet transplantation can also deliver
complete abolition of severe hypoglycemia with near-
normalization of glucose control, albeit at the cost of risks of
immunosuppression [35].
In one islet, center, over 70% of patients referred with se-
vere recurrent problematic hypolycameia were able to resolve
their issues with recurrent hypoglycaemia with conventional
treatment alone [35].
Other Options
Pancreas and islet transplantations both offer treatment for
IAH and severe hypoglycemia in patients with T1DM.
Fig. 1 Stepwise approach to
recurrent severe hypoglycaemia.
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Whole-organ pancreas transplants offer a higher rate of insulin
independence compared to islets [36]; however, the procedure
carries more risks and is associated with a higher complica-
tions rate [36] and is contraindicated in patients >60 years old
and in patients and in those with a high cardiovascular risk.
Therefore, in patients without these contraindications, there
needs to be a discussion between the patient and the transplant
team as to which would be the best option in each case.
Another important factor to take into consideration is the
kidney function of the patient at the time of assessment. ICTs
are contraindicated in patients with chronic kidney disease (i.e.,
eGFR <60 mL/min/1.73 m2) due to the risk of triggering end-
stage renal failure by the use of immunosuppressive therapy.
This group of patients often cause a clinical conundrum, requir-
ing careful consideration of the pros and cons of risk of on-going
severe hypoglycaemia versus the risks of accelerating any de-
cline in renal function [37, 38]. Wherever possible, minimizing
hypoglycaemia with the use of education and technology, with
early liaison with renal teams to minimize any delays in listing
for pre-emptive simultaneous islet or pancreas transplant with a
kidney transplant would be the preferred option [34].
Suitability for Islet Transplantation?
For most ICT programs, the indication is recurrent severe
hypoglycemia despite optimal medical management as de-
scribed above (Table 1). Inclusion criteria included the follow-
ing: age 18–65 years, T1D for ≥5 years, absent stimulated C-
peptide, IAH, and/or marked glycemic lability. If a patient
meets those criteria, it is usually important to evaluate some
other criteria, that identify those with likely optimal outcomes
based on published data.
For example, the CITR concluded that preservation of graft
function (C-peptide ≥0.3 ng/mL) post final infusion is maxi-
mized by recipient age ≥35 years, baseline LDL<75, ≥500 K
IEQs infused, use of Serva/NB1 collagenase, and calcineurin
inhibitors. With these factors combined, the retention rate re-
mains at 80% for 7–8 years. There is less agreement on the
exclusion criteria, with significant differences among trans-
plant programs; however, the most concurring contraindica-
tion is the presence of detectable C-peptide levels (>0.3 ng/ml)
[39]. Considering the two international multicenter trials: In
the Immune Tolerance Network, HbA1c >12%, BMI >26 kg/
m2, insulin requirements >0.7 UI/kg/day, creatinine >1.5 mg/
dl and/or albuminuria >300 mg/24 h, as well as the presence
of infections or psychiatric diseases were considered exclu-
sion criteria for transplantation [12, 37].
In the Clinical Islet Transplantation (CIT) Consortium
study BMI >30 kg/m2, weight ≤50 kg, insulin requirement
>1.0 UI/kg/day or <15 UI/day, HbA1c level >10%, measured
GFR <80 ml/min/1.73 m2, history of panel-reactive anti-HLA
antibodies by flow cytometry, and significant comorbid con-
ditions were considered exclusion criteria for transplantation
[15•] (Table 1).
Conclusion
IAH and severe hypoglycemia have a huge impact on the quality
of life of a substantial number of patients with T1DM. Following
an evidence-based algorithm can resolve issues with severe hy-
poglycemia for a large proportion of patients and should be
attempted. However, some patients continue to have problems
with hypoglycemia despite these interventions, and for those
current ICToffers complete resolution of SHEwith near normal-
ization of glucose control. The selection for the right candidate
for this therapy is based on balancing the benefits (problematic
hypoglycemia, improved glycemic control) against the risks
(immunosuppression) for each individual case. Given the limited
supply of organs for islet transplantation, it is important to select
those who have most to benefit, and in whom other conventional
strategies have been unsuccessful.
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Table 1 Summary of indications and contraindications for islet cell
transplantation
Indications for ICT
• Recurrent severe hypoglycaemia, including IAH or severe glycemic
lability which is resistant to intensive insulin therapy
• Undetectable C-peptide levels (<0.3 ng/ml)
• 18–65 years old
• >5 years since diagnosis of T1DM
Absolute contraindications for ICT
• Detectable C-peptide levels (>0.3 ng/ml)
Relative contraindications for ICT
• Insulin requirements (>0.7 units/kg/day) or <15units/day
• HbA1c >10%
• BMI >26 kg/m2 or weight <50 kg
• Creatinine >1.5 mg/dl and/or albuminuria >300 mg/24 h or
measured GFR <80 ml/min/1.73 m2,
• Untreated arterial disease
• History of panel reactive anti-HLA antibodies
• Significant comorbidities
ICT islet cell transplantation, IAH impaired awareness of hypoglycaemia,
T1DM type 1 diabetes mellitus, BMI body mass index, HLA human leu-
kocyte antigen
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